Clinical trials: Obese Subjects
Weight Loss
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735…
- Trial name
- NCT06828055
- Testing
- VK2735
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
- Trial name
- NCT00112021
- Testing
- pramlintide acetate
- Where
- 21 sites in United States
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Obesity
Efficacy Study of Betahistine on Body Weight in Obese Female Subjects
The purpose of this study is to examine the effect of betahistine on body weight in obese female subjects
- Trial name
- NCT00748436
- Testing
- betahistine dihydrochloride
- Where
- 12 sites in Belgium, Germany and 1 more
- Volunteers
- 187 people
- Sponsor
- OBEcure Ltd.
Type 2 Diabetes Mellitus
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)
The purpose of this study is to assess the multiple rising dose safety/tolerability and pharmacokinetics of MK-5823 in overweight/obese participants who are healthy and overweight/obese participants with Type 2 diabetes mellitus…
- Trial name
- NCT01614782
- Testing
- MK-5823
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cardiac Surgery, Sternal Wound Infection
Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection
The purpose of this study is to determine whether the gentamicin-collagen sponge is safe and effective in preventing sternal wound infections in patients undergoing cardiac surgery who are at a greater risk of developing sternal…
- Trial name
- NCT00600483
- Testing
- gentamicin-collagen sponge dipped in saline
- Where
- 43 sites in United States
- Volunteers
- 1,502 people
- Sponsor
- Innocoll
Overweight , Obesity
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving ≥ 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight/obesity.
- Trial name
- NCT07230119
- Testing
- Zovaglutide dose 1, Zovaglutide dose 2
- Where
- 45 sites in China
- Volunteers
- 755 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity
A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects
The ReShape Post Approval Study is a prospective multicenter study of the ReShape(TM) Integrated Dual Balloon System in Obese Subjects.
- Trial name
- ReShapePAS (NCT02927665)
- Testing
- Reshape Integrated Dual Balloon
- Where
- 14 sites in United States
- Volunteers
- 186 people
- Sponsor
- ReShape Lifesciences
PreDiabetes, Pre Diabetes
STAR Study Investigating Performance and Safety of the Medical Device SiPore15™
The primary objective of STAR01 is to evaluate the performance and safety of the medical device (class IIb) SiPore15™ after a 12-week long treatment in the target population of obese and overweight subjects with prediabetes or…
- Conditions
- PreDiabetes, Pre Diabetes, Prediabetic State, Type2 Diabetes
- Trial name
- NCT03823027
- Testing
- SiPore15™
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 43 people
- Sponsor
- Sigrid Therapeutics AB
Obese
Safety and Pharmacokinetics of HU6
Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Twelve subjects will be randomized (1:1) to treatment sequence to determine the order in which they will receive the tablet or capsule formulation in Period 1…
- Trial name
- NCT05433506
- Testing
- HU6 Tablet, HU6 Capsule
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rivus Pharmaceuticals, Inc.
Diabetes Melliuts, Type 2
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
This is a trial in obese subjects who have poor lipid control with and without Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple doses of PF-05231023
- Trial name
- NCT01673178
- Testing
- 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023
- Where
- 17 sites in United States
- Volunteers
- 107 people
- Sponsor
- Pfizer
Obesity & Overweight
A Study of SGB-7342 in Subjects With Obesity or Overweight
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.
- Trial name
- NCT07324850
- Testing
- SGB-7342
- Volunteers
- 45 people
- Sponsor
- Suzhou Sanegene Bio Inc.
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
- Trial name
- NCT03235050
- Testing
- MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose
- Where
- 119 sites in United States, Bulgaria and 6 more
- Volunteers
- 834 people
- Sponsor
- AstraZeneca
Obesity
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
- Trial name
- NCT07291232
- Testing
- ABBV-295
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- AbbVie
Insulin Resistance
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028
Adiponectin has been known to play critical roles in various physio-regulatory processes, and adiponectin deficiency may contribute to insulin resistance. (PEG)-BHD1028 was developed as an agonist of adiponectin receptors.
- Trial name
- NCT06563115
- Testing
- (PEG)-BHD1028 Single Ascending Dose, (PEG)-BHD1028 Multiple Ascending Dose
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- EncuraGen, Inc
Obesity
A Study of the TransPyloric Shuttle™ (TPS™) for Weight Reduction in Obese Subjects
The purpose of this study is to assess the feasibility of the TransPyloric Shuttle™ (TPS™) when used to treat obesity.
- Trial name
- NCT01386905
- Testing
- BAROnova™ TransPyloric Shuttle™ (TPS™)
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- BaroNova, Inc.
Overweight and Obesity
Efficacy of Palatinose™ Versus Sucrose on Flow Mediated Dilation in Healthy Subjects With Mild Hypertension
To determine the efficacy of Palatinose versus sucrose on Flow Mediated Dilation (FMD) in healthy subjects with mild hypertension.
- Trial name
- NCT03986775
- Testing
- isomaltulose, sucrose
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Beneo-Institute
Obesity, Overweight
A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function
This is an open-label, non-randomized study to assess how VCT220 is absorbed, distributed, metabolized, and eliminated after a single oral dose.
- Trial name
- NCT06938529
- Testing
- VCT220
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Healthy Subjects
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose…
- Trial name
- NCT07102251
- Testing
- HEC-007 injection
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Overweight, Obesity
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
The study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.
- Trial name
- NCT06904105
- Testing
- HRS-7535 Tablets
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity
Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.
- Trial name
- NCT02243202
- Testing
- Canagliflozin, Phentermine
- Where
- 17 sites in United States
- Volunteers
- 335 people
- Sponsor
- Janssen Research & Development, LLC